Top Medical News

Mirtazapine and Carbamazepine Fail to Demonstrate Clinical and Cost Effectiveness as Alzheimer Agitation Treatments

December 03, 2022

By Marco Meglio

Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.

NeurologyLive® Friday 5 — December 2, 2022

December 02, 2022

By NeurologyLive® Staff

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

Brexpiprazole Continues to Demonstrate Efficacy as Alzheimer Agitation Therapy Across Multiple Phase 3 Trials

December 02, 2022

By Marco Meglio

Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.

Episode 78: A Virtual Reality Platform for Parkison Disease

December 02, 2022

By Matt Hoffman

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Amyloid Copathology Not a Factor in Pharmacodynamic Effect of Irsenontine in Dementia With Lewy Bodies, Parkinson Disease Dementia

December 01, 2022

By Marco Meglio

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

Featured

Latest Videos

Insomnia Treatment Selection: DORA

S1P Receptor Modulator Treatment in Female Patients with MS

Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple Sclerosis

Using Semiology to Improve Epilepsy Clinical Trials: Jacqueline French, MD

Understanding the Safety Profile of Lecanamab: Marwan Sabbagh, MD, FAAN

Donanemab Outperforms Aducanumab in Amyloid Clearance, FDA Grants Priority Review to SRP-9001, Atogepant Improves PROs

Shifting the Paradigm of Clinical Research in Alzheimer Disease With the COCOA Trial: Jared Roach, MD, PhD

Addressing Unmet Needs of Dementia With Lewy Bodies: James Galvin, MD, MPH

Behavioral Lifestyle Interventions to Improve Cognitive Outcomes for Alzheimer Disease: Jared Roach, MD, PhD

The Expectations for the 2023 MDA Conference: Donald S. Wood, PhD; Sharon Hesterlee, PhD

Expanding the Biomarker Panel in MS: Jens Kuhle, MD, PhD

Dual Orexin Receptor Antagonist (DORA) for Treatment of Insomnia

Sleep and Wakefulness Pathways

Most Recent

Insomnia Increases Risk of Subjective Memory Decline in Middle-Aged and Older Adults

December 01, 2022

Article

Results from a longitudinal study suggest that higher proportions of subjective memory decline are associated with insomnia disorder in middle-aged and older adults.

Targeting Inflammation to Reduce Effects of Alzheimer Disease: RJ Tesi, MD

December 01, 2022

Video

The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

December 01, 2022

Article

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

ACI-35.030 and JACI-35.054 Vaccinations Demonstrate Safety in Early Alzheimer Disease

November 30, 2022

Article

An ongoing phase 1b/2a clinical trial showed that both the ACI-35.030 and JACI-35.054 vaccines are safe as a treatment for patients in the earlier stages of Alzheimer disease, the authors suggested ACI-35.030 suggested as the superior vaccine candidate.

Longitudinal Study to Investigate Health and Lifestyle Behavior Effects on MS: Michelle Chen, PhD

November 30, 2022

Video

The neuropsychologist at Rutgers University spoke about her recently awarded NIH grant to study the impact of health and lifestyle behaviors in individuals with MS. [WATCH TIME: 3 minutes]

Duchenne Gene Therapy SRP-9001 Wins Priority Review

November 30, 2022

Article

The PDUFA date for SRP-9001, developed in partnership between Sarepta and Roche, is set for May 29, 2023. The BLA was submitted for accelerated approval.

Music-Based Application to Improve Insomnia in Patients With Dementia and Their Caregivers: Darina Petrovsky, PhD, RN

November 30, 2022

Video

The assistant professor, Rutgers University, New Brunswick, New Jersey, offers an overview on her ongoing lab project about a music-based intervention to improve insomnia in dementia and caregivers. [WATCH TIME: 3 minutes]

NeuroVoices: Carrie Hersh, DO, MSc, on Applying 2-Stage Models to Improve Disease-Modifying Therapy Selection in MS

November 30, 2022

Article

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

November 30, 2022

Article

In the pivotal phase 3 Clarity AD trial, lecanemab (Biogen) demonstrated significant impacts on primary and secondary end points, with additional promising results on biomarker analyses and safety.

Digital Treatment Approach May Help Reduce Healthcare Burden for MS Fatigue: Federica Picariello, PhD

November 29, 2022

Video

The postdoctoral researcher and health psychologist at King's College London spoke at ECTRIMS 2022 about the digital approach to treating fatigue in multiple sclerosis and the lack of available measurements. [WATCH TIME: 3 minutes]

Latest SAP Content

Using Semiology to Improve Epilepsy Clinical Trials: Jacqueline French, MD

Addressing Unmet Needs of Dementia With Lewy Bodies: James Galvin, MD, MPH

Episode 78: A Virtual Reality Platform for Parkison Disease

Longitudinal Study to Investigate Health and Lifestyle Behavior Effects on MS: Michelle Chen, PhD

View More SAP Content